Michael Morse

Professor of Medicine
Michael Morse

Overview

We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Positions

Professor of Medicine in the School of Medicine

2012 School of Medicine

Professor in the Department of Surgery in the School of Medicine

2015 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

1993 School of Medicine

Education

M.D. 1990

1990 Yale University

Medical Resident, Medicine

1993 University of Washington

Fellow in Hematology-Oncology, Medicine

1996 Duke University

Clinical Trials

View All

Publications, Grants & Awards

DCI Centers, Cancer Types & Labs

Offices & Contact

Duke Box 3233
Durham, NC
27710
Seeley G. Mudd Bldg, Rm 437, 10 Bryan Searle Dr.
Durham, NC
27710